PIONEER: A Multicenter, Open-Label, Randomized Phase II Trial of Second-Line Apatinib Plus Chemotherapy Versus Chemotherapy Alone in Gastric and Gastroesophageal Junction Adenocarcinoma (GA/GEA) Refractory to or Intolerant of Prior Anti-Pd-1 Therapy